Immunotech Biopharm's (HKG:6978) CAR-T-19 obtained breakthrough therapy designation for treating patients aged 25 and below with relapsed/refractory B-cell acute lymphoblastic leukemia.
The designation, granted by the Center for Drug Evaluation of China's National Medical Products Administration, will expedite the clinical development of CAR-T-19.
The designation was awarded based on the "solid" clinical efficacy and safety data of CAR-T-19, Immunotech said in a Wednesday filing with the Hong Kong Exchange.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。